Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback